EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Novel ABCA1 mutations in Tangier disease associated with early‐onset type 2 diabetes: A case report

Makoto Wada, Naoko Saito‐Sato, Masaki Tanaka, Junko Nomoto, Aki Watanabe, Masayuki Kuroda, Yoshiro Maezawa, Tetsuta Sato, Yusuke Yagyu, Shuji Toriumi, Amika Kajiyama, Takahide Hashimoto, Naoki Ohtake, Masaya Yamaga, Tomohiko Yoshida, Shoji Tsuji, Minoru Takemoto

Journal of Diabetes Investigation · 2026-11-07

DOI: 10.1111/jdi.70483 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Tangier disease (TD) is a rare disorder caused by mutations in the ATP‐binding cassette transporter A1 (ABCA1) gene with autosomal recessive inheritance and is characterized by extremely low high‐density lipoprotein cholesterol (HDL‐C) and premature atherosclerosis. Although experimental studies suggest that ABCA1 plays an important role in pancreatic β ‐cell cholesterol homeostasis, its clinical contribution to diabetes development in humans remains unclear. We report a 69‐year‐old Japanese man with early‐onset type 2 diabetes mellitus, profound hypo‐HDL cholesterolemia (HDL‐C 5 mg/dL), and severe atherosclerotic cardiovascular disease. Genetic analysis identified compound heterozygous ABCA1 variants (p.Arg104Cys and the novel p.Asp1706Tyr), both of which were predicted to be potentially pathogenic, although direct functional validation was not performed. Despite a 40‐year duration of diabetes, endogenous insulin secretion was partially preserved. This case highlights phenotypic variability in TD and suggests that variant‐specific effects on ABCA1 function and polygenic susceptibility may influence diabetes development in humans.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →